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Abstract
Objective—To examine the prevalence of vitamin D insufficiency and the associations of
vitamin D concentration with disease status in African Americans with rheumatoid arthritis (RA).
Methods—Study participants (n = 266) were enrolled in the Consortium for the Longitudinal
Evaluation of African Americans with Early RA (CLEAR) Registry. 25(OH)-D was measured on
baseline plasma and associations of 25(OH)-D with disease status (baseline and at 3 years disease
duration) were examined using univariate and multivariate regression.
Results—The prevalence of 25(OH)-D insufficiency (≤ 37.5 nmol/L or 15 ng/ml) was 50%, with
the highest prevalence in winter. In unadjusted analyses, vitamin D concentrations were inversely
associated with baseline pain (p = 0.04), swollen joints (p = 0.04), and Disease Activity Score
(DAS-28, p = 0.05) but not with measures at 3 years disease duration. There were no multivariate
associations of 25(OH)-D with any disease measures at baseline or at 3 years with the exception of
a positive borderline association with rheumatoid factor positivity at enrollment (p = 0.05).
Conclusions—Vitamin D insufficiency is common in African Americans with recent-onset RA.
Unadjusted associations of circulating vitamin D with baseline pain, swollen joints, and DAS-28
were explained by differences in season, age, and gender and were not significant in multivariate
analyses. In contrast to reports of Northern Europeans with early inflammatory arthritis, there are
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not strong associations of 25(OH)-D concentration with symptoms or disease severity in African
Americans with RA.
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Introduction
The immunomodulatory effects of vitamin D have been subject to extensive examination,
leading to recent speculation that it may play a role in select inflammatory diseases
including rheumatoid arthritis (RA). Vitamin D and its analogues have been shown to
suppress T-cell proliferation and inhibit the expression of pro-inflammatory cytokines
involved in RA pathogenesis including interleukin (IL)-2 and interferon- γ [1, 2]. Likewise,
vitamin D receptors are constitutively expressed on activated lymphocytes, synoviocytes,
macrophages, and chondrocytes in the RA lesion [3] while vitamin D metabolites are
increased in RA synovial fluid [4]. In at least one epidemiological study, vitamin D intake
was inversely associated with the risk of developing new-onset RA [5], though conflicting
results have been reported [6, 7]. Although investigations of its association with disease
activity in RA are limited, preliminary data suggest that levels of circulating vitamin D are
inversely associated with disease activity in patients of European ancestry with early
inflammatory arthritis [8].
Vitamin D insufficiency has consistently been found to be more prevalent in African
Americans than in other racial/ethnic populations [9–11], possibly related to decreased
dietary intake and reduced vitamin D synthesis among individuals with darker skin
pigmentation [9, 12]. Data from the Third National Health and Nutrition Examination
Survey (NHANES III) demonstrated that, in southern U.S. states, 53–76% of non-Hispanic
blacks compared with only 8%–33% of non-Hispanic whites had insufficient levels of 25-
hydroxy-vitamin D (25(OH)-D) [10]. Given the higher prevalence of insufficiency in
African Americans, in combination with its potential role in both the incidence and severity
of RA, we examined vitamin D status and its associations with disease activity and disease
severity in well characterized group of African Americans with recent-onset RA.
Methods
Study Population
Study subjects were participants in the Consortium for the Longitudinal Evaluation of
African-Americans with Early Rheumatoid Arthritis (CLEAR), a multicenter registry of
African Americans with RA [13]. Subjects were enrolled from four academic medical
centers in the southeast U.S. (University of Alabama at Birmingham, Emory University,
Medical University of South Carolina, and the University of North Carolina). There were
266 study subjects with available baseline data (including banked plasma samples) and 191
subjects with data from both baseline and 36-month disease duration (time elapsed since
symptom onset). Based on the study design, the elapsed time from enrollment to the 36-
month visit varied from a minimum of one year to a maximum of 3 years. The study was
approved by the Institutional Review Board at each participating center. All study subjects
provided informed written consent, met the American College of Rheumatology (ACR) RA
classification criteria [14], had less than two years of disease duration from time of first
symptom onset, and self-reported African American race/ethnicity.
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25(OH)-D was measured using baseline plasma samples and a commercially available
radioimmunoassay (Immunodiagnostic Systems Limited, Boldon, U.K.). The intra-assay
coefficient of variation was 7.7%. Additional assessments of 25(OH)-D during follow-up
were not available. To facilitate comparisons with other non-RA African American
populations [11], vitamin D insufficiency was defined as a 25(OH)-D concentration ≤37.5
nmol/L (15 ng/ml), a threshold used in previous investigations of older Caucasian
populations [15–18]. 25(OH)-D was studied rather than the more active form (1,25-
dihydroxyvitamin D [1,25(OH)2D]), because reported associations with disease activity
have been shown to be stronger for 25(OH)-D [8]. 25(OH)-D acts as a substrate for
1,25(OH)2D, levels of which are also dependent on calcium and phosphorus status in
addition to parathyroid hormone concentrations, measures not available for the participants
in this study.
Measures of RA Disease Activity and Severity
In addition to 25(OH)-D levels, baseline evaluations included tender and swollen joint
counts (0–28), high sensitivity C-reactive protein (hs-CRP, mg/L), rheumatoid factor (RF-
IgM) positivity, anti-cyclic citrullinated peptide (anti-CCP) antibody positivity, the Health
Assessment Questionnaire Disability Index (HAQ, range 0–3) [19], pain (0–10),
subcutaneous nodules (present vs. absent), prior use of glucocorticoids, self-reported
comorbidity (including a history of liver disease, renal disease, or inflammatory bowel
disease), and use of disease-modifying anti-rheumatic drugs (DMARDs) at enrollment.
DMARDs included methotrexate, anakinra, azathioprine, etanercept, gold salts (oral or
intramuscular), leflunomide, hydroxychloroquine, sulfasalazine, and infliximab. There were
no patients taking cyclosporine, cyclophosphamide, or adalimumab (the latter, not available
at the time of study enrollment for many patients). We also examined associations of
vitamin D concentration with a three-variable Disease Activity Score-28 at enrollment
calculated using the Nijmegen formula, substituting a hs-CRP for a standard CRP and
accounting for the difference in units of measurement (DAS28 = [0.56*sqrt (tender joint
count) + 0.28*sqrt (swollen joint count) + 0.36*ln (hsCRP = 1)] * 1.10 + 1.15)
(http://www.reuma-nijmegen.nl/www.das-score.nl/index.html). The methods of
autoantibody measurements and assessments of corresponding metric/diagnostic properties
in this population have been previously reported [20]. There were 9 patients with missing
values for both anti-CCP antibody and RF-IgM. In addition, baseline radiographs of the
hands and wrists (available for 184 patients at enrollment) were scored using van der Heijde
modified Sharp score [21] and subjects were categorized by the presence or absence of
radiographic erosions (erosion score ≥1 vs. erosion score = 0). This threshold was used
rather than an erosion score of ≥2 to 3 based on the low proportion of subjects meeting this
threshold at baseline (10% and 7%, respectively). At 36-months disease duration (n = 191
subjects with baseline and 36-month follow-up data), tender and swollen joint counts, HAQ,
radiographic severity (n = 134), and pain were reassessed on subjects with available follow-
up. DAS-28 measures were not examined at 36-months of disease duration because hs-CRP
measures were not available for this time point.
Statistical Analysis
The prevalence of vitamin D insufficiency (25(OH)-D level ≤37.5 nmol/L, equivalent to
≤15 mg/ml) was examined in the overall study population in addition to subgroups that
included women of reproductive age (18 to 49 years) and excluding those taking vitamin D
supplements. Ninety-five percent confidence intervals (95% CIs) were generated for all
prevalence estimates using the logit Wald interval, which inverts a Wald-type interval for a
logit scaled prevalence [22]. Similarly, we examined the prevalence of vitamin D deficiency,
defined as a 25(OH)-D level ≤25 nmol/L (10 ng/ml). Based on recent reports suggesting
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optimal 25(OH)-D concentrations should be defined as ≥80 nmol/L (32 ng/ml) in
Caucasians [23], we also examined the prevalence of insufficiency using this cutoff.
25(OH)-D concentrations below 78 nmol/L (31 ng/ml) have been shown to lead to
elevations in circulating intact parathyroid hormone (iPTH) concentrations [24]. Chi-square
tests and Wilcoxon rank sum tests were used to compare categorical and continuous
variables for those with insufficiency vs. individuals with 25(OH)-D levels above this
threshold. Variables examined in association with vitamin D status included age, gender,
ever smoking, prior or current use of glucocorticoids, DMARD use, vitamin D supplement
use at enrollment, educational level (≥high school education vs. other), current alcohol use,
body mass index (BMI, kg/m2), disease duration, season of study enrollment (summer - June
21st through September 20th, fall – September 21st through December 20th, winter
December – 21st through March 20th, or spring- March 21st though June 20th) in addition to
the aforementioned measures of RA disease activity and severity.
The associations of continuous 25(OH)-D concentrations (per 10 nmol/L increments) with
measures of disease activity and severity (at baseline and 3 years disease duration) were first
examined using univariate regression analyses (logistic regression for dichotomous
outcomes and linear regression for continuous outcomes). All outcome variables were
modeled separately and, given possible co-linearity, were not included as covariates in
models of other outcomes. As previously reported [8], multivariate regression analyses were
then performed adjusting for age, gender, and season of enrollment. All analyses involving
36-month disease duration outcomes were adjusted for the corresponding baseline measure.
Using additional models, we also examined the impact of including glucocorticoid and
DMARD use in addition to BMI as covariates, particularly since a higher BMI has been
associated with lower circulating concentrations of vitamin D (a fat soluble vitamin) [11].
All analyses were performed using SAS v9.1 (SAS Inc., Cary, NC).
Results
Patient characteristics
Baseline sociodemographic, health, and disease-specific characteristics of study participants
are shown in Table 1 (n = 266). Women comprised 81% of the study participants; RA
patients had a mean age of 51 years and disease duration just over one year. Over one-half
of participants had a history of smoking, while the mean BMI was more than 30 kg/m2.
There were 40 patients using vitamin D supplements, including 15 women of reproductive
age. The most common season of study enrollment was winter (29%), followed by spring
(27%), summer (26%), and fall (18%). Overall, the mean (± S.D.) concentration of 25(OH)-
D was 40.5 (± 15.6) nmol/L. The frequency of self-reported health conditions that might
impact 25(OH)-D concentrations including liver disease (2.9%), kidney disease (6.1%), and
inflammatory bowel disease (2.5%) was low.
Measures of RA disease activity and severity
Study participants had disease related measures at enrollment suggestive of moderate to
severe disease with a mean HAQ score of 1.6 and mean swollen and tender joint counts of 5
and 8, respectively (Table 1). A majority of patients had received prior glucocorticoid
therapy (80%) and most (84%) were receiving DMARDs at enrollment. The mean plasma
hs-CRP was elevated (15.7 mg/L, normal ≤3 mg/L), while 14% had rheumatoid nodules,
60% were anti-CCP antibody positive, and 69% were RF positive. Twenty-seven percent of
participants’ baseline films demonstrated radiographic erosions. Clinical measures available
at 36-months disease duration (n = 191) included HAQ score (mean = 1.46, S.D. = 1.00),
swollen joint count (mean = 3.8, S.D. = 5.6), tender joint count (mean = 6.4, S.D. = 8.2), and
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pain (mean = 6.1, S.D. = 5.4), and the presence of radiographic erosions (41%) (data not
shown).
Prevalence of vitamin D insufficiency and deficiency
The overall prevalence of vitamin D insufficiency (≤37.5 nmol/L) was 49.6% (95% CI
43.6% to 55.6%) (Figure 1), a frequency that increased to 52.2% (95% CI 45.7% vs. 58.7%)
when subjects taking vitamin D supplements were excluded (n = 40). Vitamin D
insufficiency was more common in women of reproductive age (18–49 years) with a
prevalence of 55.7% (95% CI 46.1% to 64.8%), a frequency that increased only slightly
after the exclusion of women taking vitamin D supplements (57.1%; 95% CI 46.8% to
66.9%). Factors associated with vitamin D insufficiency included younger age, the absence
of vitamin D supplementation (11% with vitamin D insufficiency reported supplement use
vs. 20% in those with sufficient levels, p = 0.04), current alcohol use (22% of insufficient
patients vs. 11% of others, p = 0.01) and season of enrollment (p = 0.0003).
Vitamin D deficiency (≤25 nmol/L) was observed in 14.7% of patients (95% CI 10.9% to
19.4%). Using the recently suggested threshold of 80 nmol/L [23], vitamin D insufficiency
was nearly universal (98.5%; 95% CI 96.1% to 99.4%). Using this threshold, there was a
single woman of reproductive age with adequate concentrations of circulating 25(OH)-D.
Rates of vitamin D insufficiency (≤37.5 nmol/L) based on season of enrollment are shown
in Figure 1. The highest prevalence was observed for those enrolled during winter
(prevalence = 68.4%; 95% CI 57.2% to 77.8%) with the lowest prevalence during summer
(prevalence = 35.7%; 95% CI 25.4% vs. 47.5%). Similar seasonal variation was observed
with vitamin D deficiency (25(OH)-D ≤25 nmol/L) with the highest prevalence in winter
(prevalence = 21.0%; 95% CI 13.3% to 31.6%) although the lowest prevalence was
observed in the fall (prevalence = 4.1%; 95% CI 1.0% to 14.9%).
Associations of vitamin D with measures of RA disease activity/severity
In unadjusted analyses, baseline 25(OH)-D levels were inversely associated with baseline
pain scores (β-coefficient −0.24, p = 0.04, per 10 nmol/L), swollen joint counts (β-
coefficient −0.49, p = 0.04), and DAS-28 (β-coefficient −0.11, p = 0.05) (Table 2). There
were no associations with other measures of disease activity or severity at baseline or any of
the outcomes assessed at 36-months of disease duration (Table 2). The associations of
vitamin D concentration with baseline pain, swollen joint counts, and DAS-28 scores were
attenuated and not statistically significant after multivariate adjustments for age, gender, and
season of enrollment. Of the covariates modeled, age had the strongest confounding effects
on baseline pain (β = −0.041, p = 0.003) and DAS-28 (β = −0.014, p = 0.04) while season of
enrollment (β = −0.14 to −1.30, p > 0.1) had the strongest association with swollen joint
counts (data not shown). Although not significant in univariate analysis, higher
concentrations of 25(OH)-D were positively associated with seropositivity for RF-IgM (OR
= 1.22; 95% CI 1.00 to 1.49; p = 0.05, per 10 nmol/L increase) after adjusting for age,
gender, and season. This association was attenuated and not statistically significant after
additional adjustment for BMI (p = 0.08) (data not shown). None of the multivariate results
were significantly changed after additional adjustment for glucocorticoid or DMARD use
(data not shown).
Discussion
Our patient population demonstrated high rates of vitamin D insufficiency (50%) that were
in accordance with data from national population-based studies, underscoring the relatively
high prevalence of vitamin D insufficiency in African-Americans [10, 11]. Recognizing the
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limitations of making comparisons across studies, the frequency of vitamin D insufficiency
in reproductive-aged African American women with RA (56%) appears to be higher than
that previously reported in a national study (NHANES-III) of a similar non-RA population
(42%) [11]. In contrast to our a priori hypothesis, we observed no conclusive associations of
vitamin D concentrations with disease activity or severity. Although baseline pain, swollen
joints, and DAS-28 scores were inversely associated with vitamin D concentration in
univariate analyses, these associations failed to meet statistical significance following
multivariate adjustments, suggesting that this association is explained primarily by
differences in age and season of assessment. Although of borderline significance and
potentially representing a spurious finding, the association of 25(OH)-D concentration with
RF seropositivity was not anticipated.
The results observed in this study with respect to the association of vitamin D status and
self-reported pain may not be surprising given conflicting literature regarding
hypovitaminosis D and musculoskeletal pain. Previous studies have suggested a link
between low vitamin D and musculoskeletal pain [25, 26], and some have even suggested
that patients with chronic pain should be routinely screened for hypovitaminosis D [27].
More recently, the notion of an association between pain and vitamin D status has been
refuted [28, 29]. Furthermore, treatment of hypovitaminosis D does not appear to be
effective in management of patients with chronic pain [29].
Our results conflict with those of Patel and colleagues [8], a report that showed evidence of
an inverse relationship between vitamin D concentrations and measures of disease activity in
early inflammatory arthritis both at baseline and after 1 year of follow-up. Specifically, these
investigators observed inverse associations between 25(OH)-D and baseline tender joint
counts, Disease Activity Score 28-joint assessment (DAS28) score, and HAQ score, with
only the associations with HAQ score remaining significant after 1 year of follow-up.
Interestingly, associations of vitamin D status with pain scores were not examined in this
population [8]. There are several factors that may account for the differences observed
between the present study and previous findings, mainly with respect to differences in the
study populations (i.e. RA in the present study vs. inflammatory arthritis, African-
Americans vs. Northern Europeans, and differences in exposure to therapies including
glucocorticoids and DMARDs). Patients in the study of Patel et al were ‘treatment naive’ at
baseline, enrolled within six months of disease onset with a cumulative DMARD use of less
than six weeks in duration. In contrast, patients in the present study had disease durations of
up to two years at enrollment and most patients had received therapy for their RA for at least
a limited duration of time, reflected in the high rate of DMARD and current or past
glucocorticoid use. Recognizing these potentially important study differences, our results
call in to question the role of vitamin D status as an important disease modifier, at least in
this population.
As noted, the results of this investigation are specific to African-Americans with recent
onset RA, which limits the generalizability of these findings. Despite its high prevalence, the
precise impact of hypovitaminosis D in African Americans has not been well established
and preliminary data suggests that the physiological effects of vitamin D concentration may
differ by race/ethnicity. Compared to Caucasians, African Americans appear to be less
sensitive to changes in circulating 25(OH)-D with respect to bone mineral density [30]. It is
conceivable that African Americans may also be less sensitive than Caucasians to the effects
of vitamin D status in relation to its effects on other disease pathways including systemic
inflammation in RA. Further studies aimed at improving our understanding of racial/ethnic
differences in the anti-inflammatory effects of vitamin D could provide insight into RA
pathogenesis with potential application to other diseases in which hypovitaminosis D has
been implicated.
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It is worth noting that the threshold used to define vitamin D insufficiency (≤37.5 nmol/L)
in this study might be considered conservative. This threshold was used primarily to
facilitate historical comparisons with reports from other African American populations [11].
Recently, different authors have argued in support of optimal 25(OH)-D levels as high as 75
to 80 nmol/L, levels based primarily on fracture prevention data also derived from older
Caucasian populations [23, 31]. As our data clearly illustrate, using higher thresholds
renders hypovitaminosis D nearly universal among African Americans with recent-onset
RA. Indeed, an optimal threshold and the potential benefit of increased vitamin D intake in
African Americans remain to be defined [32]. Given the potential consequences of vitamin
D deficiency with the risk of other chronic diseases including diabetes, multiple sclerosis,
malignancy, and heart disease [33, 34], its health implications in African Americans
(including those with RA) may extend well beyond bone health and musculoskeletal disease.
There are limitations to this study. Study participants were enrolled in the Southeast U.S.
where sun exposure rates (and resulting vitamin D concentrations) may differ significantly
with other populations from other geographic regions. It is possible, for instance, that
African Americans with RA from northern latitudes may have a substantially higher
prevalence of hypovitaminosis D. Our study also lacks from limited follow-up, as vitamin D
status was assessed only at baseline, and disease activity recorded at enrollment and after 3
years of disease duration with the latter available for a majority of patients. Although study
participants had a limited disease duration at the time of enrollment, it is impossible to
exclude the possibility of unmeasured confounding from different RA treatments received,
varying amounts of sun exposure, and dietary intake of vitamin D. However, we would
anticipate that confounding secondary to the effect of RA on mobility, sun exposure, and
nutritional status would have resulted in even stronger associations with measures of disease
activity, particularly HAQ scores. Despite its limitations, the study has notable strengths.
This is the largest study to date examining the impact of vitamin D status in African
Americans with RA, a vastly understudied population. Although vitamin D concentrations
do not appear to play a major role in RA disease activity in this population, the high
prevalence of hypovitaminosis D underscores the critical need for additional studies
examining the longer term effects of vitamin D status in African Americans with RA.
In summary, Vitamin D insufficiency is common in African Americans with recent-onset
RA, affecting approximately half of this population. Associations of lower concentrations of
circulating vitamin D with increased pain, higher swollen joint counts, and DAS-28 values
in this group appear to be primarily related to differences in season, age, and gender and
were not significant in multivariate analyses. In contrast to reports of Northern Europeans
with early inflammatory arthritis, there are not strong associations of 25(OH)-D
concentration with symptoms or disease severity in African Americans with RA.
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Overall and seasonal prevalence (%) of vitamin D insufficiency in African Americans with
recent-onset rheumatoid arthritis (n = 266); frequency shown for: 1) all patients, 2) all
patients after excluding individuals using vitamin D supplements, 3) women of reproductive
age (18 to 49 years), and 4) women of reproductive age after excluding those taking vitamin
D supplements (pooled frequency and frequency for each season of enrollment). Prevalence
(%) shown with shaded bars; 95% confidence intervals (CIs) shown with solid bars.
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